Find disease awareness content and relevant supporting materials
Real world study of SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement shows positive outcomes in aortic stenosis.- Edwards Lifesciences
Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and at low risk of death from surgery.
Six months data from CLASP IID trial of PASCAL system, confirming TEER as safe and effective for degenerative mitral regurgitation (DMR) in first head to head trial
Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR)
Results from PROTECTED TAVR study evaluating SENTINEL Cerebral Protection System for removal of embolic debris from TAVR are presented at TCT meeting
Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL Cerebral Protection System, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve replacement (TAVR) before it can reach the brain and potentially cause a stroke
FDA approves SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe symptomatic aortic stenosis patients. Edwards Lifesciences
Edwards Lifesciences Corporation announced that the SAPIEN 3 Ultra system has received FDA approval for transcatheter aortic valve replacement in...